Inventor · disambiguated record
Xiaowu Liu
Also filed as: LIU XIAOWU
3 granted patents·8 pending applications·45 citations·filing 2010–2022
61Inventor score
Files withSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD6HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD1LIU XIAOWU1SHANGHAI BENEMAE PHARMACEUTICAL CORP1SHANGHAI SENHUI MEDICINE CO LTD1
Top patents by PatentIndex Score
11 records- 0188US8326547B2Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithmLIU XIAOWU·Filed 2010·Granted Dec 4, 2012·45 cites·20 claims
- 0257US2025042896A1Polycyclic compound as cbl-b inhibitorHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0351US2024124576A1Preparation of siglec-15 binding protein and use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0450US2025277038A1Anti-pd-l1 antibody and use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0550US2024117034A1GARP Protein Antibody and Use ThereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0648US2024141069A1Anti-masp-2 antibody and use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0748US2024287168A1Anti-vegf antibody and use thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2022·Application pending·0 cites
- 0846US2023250191A1Anti-ige engineered antibody and application thereofSHANGHAI JEMINCARE PHARMACEUTICALS CO LTD·Filed 2021·Application pending·0 cites
- 0941US11958911B2Anti-coagulation factor XI antibodySHANGHAI BENEMAE PHARMACEUTICAL CORP·Filed 2019·Granted Apr 16, 2024·0 cites·15 claims
- 1039US8603780B2Methods and compositions for enhanced expression and secretion of proteinsWANG ZHUYING·Filed 2012·Granted Dec 10, 2013·0 cites·20 claims
- 1137US2024190896A1Smtp-7 derivative and use thereofSHANGHAI SENHUI MEDICINE CO LTD·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →